RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
RenovoRx, Inc.NASDAQ: RNXT
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$64.91M, compared with -$52.64M a year earlier.
Context
- Retained earnings amounted to 464.8% of total assets at the end of Q1 FY2026, up 136.1 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -23.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (61.39M) USD
- Year-over-year change
- -22.2%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (61.39M) | -22.2% |
| FY2024 | 2024-12-31 | (50.22M) | -21.3% |
| FY2023 | 2023-12-31 | (41.41M) | -32.8% |
| FY2022 | 2022-12-31 | (31.17M) | -46.5% |
| FY2021 | 2021-12-31 | (21.28M) | — |
Retained Earnings vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's Mar 2026 retained earnings of -$64.91M is the highest of the 6 companies compared; the peer median is -$181.31M.
- Its year-over-year change of -23.3% is the 4th highest of 6, against a peer median of -19.8%.
- Retained earnings amounts to 464.8% of total assets for RNXT, versus a peer median of 1116.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$64.91M | -23.3% | — | 464.8% | |
| Mar 2026 | -$96.47M | -19.8% | — | 1335.6% | |
| Mar 2026 | -$116M | -26.4% | — | 328.4% | |
| Mar 2026 | -$181.31M | -29.2% | — | 1116.2% | |
| Mar 2026 | -$309.23M | -12.2% | — | 1613.9% | |
| Dec 2025 | -$991.48M | -10.2% | — | 923.8% | |
| Peer median (excluding RNXT) | -$181.31M | -19.8% | — | 1116.2% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.